For the quarter ending 2025-09-30, AKBA has $364,152K in assets. $322,560K in debts. $166,444K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 166,444 | 137,308 | ||
| Inventories | 18,643 | 16,708 | ||
| Accounts receivable, net | 66,223 | 72,809 | ||
| Prepaid expenses and other current assets | 7,026 | 7,832 | ||
| Total current assets | 258,336 | 234,657 | ||
| Property and equipment, net | 1,473 | 1,714 | ||
| Operating right-of-use assets | 4,837 | 5,987 | ||
| Goodwill | 59,044 | 59,044 | ||
| Other long-term assets | 40,462 | 44,193 | ||
| Total assets | 364,152 | 345,595 | ||
| Accounts payable | 10,087 | 11,554 | ||
| Accrued expenses and other current liabilities | 106,420 | 91,615 | ||
| Current portion of deferred revenue | 3,881 | 5,532 | ||
| Working capital fund liability, current portion | 12,991 | 10,016 | ||
| Total current liabilities | 133,379 | 118,717 | ||
| Long-term operating lease liabilities | 0 | 671 | ||
| Long-term debt, net | 47,641 | 47,062 | ||
| Liability related to settlement royalties, net of current portion | 52,994 | 48,729 | ||
| Liability related to sale of future royalties, net of current portion | 50,576 | 51,082 | ||
| Working capital fund liability, net of current portion | 27,726 | 30,556 | ||
| Warrant liability | 5,242 | 14,199 | ||
| Other long-term liabilities | 5,002 | 5,355 | ||
| Total liabilities | 322,560 | 316,371 | ||
| Common stock 0.00001 par value 350,000,000 shares authorized at september30, 2025 and december 31, 2024 265,226,038 and 224,848,992 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 2 | 2 | ||
| Additional paid-in capital | 1,713,045 | 1,701,217 | ||
| Accumulated other comprehensive income | 6 | 6 | ||
| Accumulated deficit | -1,671,461 | -1,672,001 | ||
| Total stockholders' equity (deficit) | 41,592 | 29,224 | ||
| Total liabilities and stockholders' equity (deficit) | 364,152 | 345,595 | ||
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)